Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

BACKGROUND: Non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitors show long lasting responses, but it is hard to predict which patients will profit from this treatment with the currently used marker, programmed death ligand 1 (PD-L1). We hypothesized that circulating tumor c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Tamminga, Menno, de Wit, Sanne, Hiltermann, T. Jeroen N., Timens, Wim, Schuuring, Ed, Terstappen, Leon W. M. M., Groen, Harry J. M.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6617698/
https://ncbi.nlm.nih.gov/pubmed/31291995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0649-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars